135 related articles for article (PubMed ID: 1888828)
1. Steady-state pharmacokinetics of enteric coated 5-amino-salicylic acid tablets in healthy volunteers and in patients with Crohn's disease or ulcerative colitis.
Norlander B; Gotthard R; Ström M
Aliment Pharmacol Ther; 1991 Jun; 5(3):291-300. PubMed ID: 1888828
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers.
Norlander B; Gotthard R; Ström M
Aliment Pharmacol Ther; 1990 Oct; 4(5):497-505. PubMed ID: 2129637
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form.
Norlander B; Gotthard R; Ström M
Aliment Pharmacol Ther; 1989 Aug; 3(4):333-42. PubMed ID: 2518847
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers.
Gionchetti P; Campieri M; Belluzzi A; Boschi S; Brignola C; Miglioli M; Barbara L
Aliment Pharmacol Ther; 1994 Oct; 8(5):535-40. PubMed ID: 7865646
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease.
Hardy JG; Healey JN; Reynolds JR
Aliment Pharmacol Ther; 1987 Aug; 1(4):273-80. PubMed ID: 2979672
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.
Healey JN
Scand J Gastroenterol Suppl; 1990; 172():47-51. PubMed ID: 2353171
[TBL] [Abstract][Full Text] [Related]
7. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
Ewe K; Becker K; Ueberschaer B
Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
[TBL] [Abstract][Full Text] [Related]
8. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
[TBL] [Abstract][Full Text] [Related]
9. Scintigraphic study of gastrointestinal transit and disintegration sites of mesalazine tablets labeled with technetium-99m.
Sciarretta G; Furno A; Mazzoni M; Ferrieri A; Malaguti P
Scand J Gastroenterol; 1993 Sep; 28(9):783-5. PubMed ID: 8235433
[TBL] [Abstract][Full Text] [Related]
10. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.
Mardini HA; Lindsay DC; Deighton CM; Record CO
Gut; 1987 Sep; 28(9):1084-9. PubMed ID: 3678967
[TBL] [Abstract][Full Text] [Related]
11. Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission.
Almer S; Norlander B; Ström M; Osterwald H
Scand J Gastroenterol; 1991 Mar; 26(3):327-35. PubMed ID: 1853156
[TBL] [Abstract][Full Text] [Related]
12. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
13. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
Rachmilewitz D
BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
[TBL] [Abstract][Full Text] [Related]
14. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine.
Larouche J; Morais J; Picard M; Lambert C; Spénard J; Landriault H; Kennedy G; Poitras P
Aliment Pharmacol Ther; 1995 Jun; 9(3):315-20. PubMed ID: 7654894
[TBL] [Abstract][Full Text] [Related]
15. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics.
Klotz U; Maier KE; Fischer C; Bauer KH
Arzneimittelforschung; 1985; 35(3):636-9. PubMed ID: 4039590
[TBL] [Abstract][Full Text] [Related]
16. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
Schreiber S; Howaldt S; Raedler A
Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910
[TBL] [Abstract][Full Text] [Related]
17. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
Maier K; Fischer C; Klotz U; Heinkel K
Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
[TBL] [Abstract][Full Text] [Related]
18. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
[TBL] [Abstract][Full Text] [Related]
19. Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?
Nakshabendi IM; Duncan A; Russell RI
Postgrad Med J; 1992 Mar; 68(797):189-91. PubMed ID: 1350343
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
